title: Selecting the Optimal Design for Drug Discontinuation Trials in a Setting of Advanced, Life-Limiting Illness-Reply.
authors.affiliation: Department of Medicine, University of Colorado School of Medicine, Aurora.
authors.forename: Jean S
authors.initials: JS
authors.lastname: Kutner
authors.affiliation: San Francisco Veterans Affairs Medical Center, Center for Research on Aging at the Jewish Home of San Francisco, San Francisco, California3Division of Geriatrics, Department of Medicine, University of California, San Francisco, San Francisco.
authors.forename: Christine S
authors.initials: CS
authors.lastname: Ritchie
authors.affiliation: Center for Learning Health Care, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
authors.forename: Amy P
authors.initials: AP
authors.lastname: Abernethy
mesh_terms: D002318:Cardiovascular Diseases; D003072:Cognition Disorders; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D009369:Neoplasms; D010166:Palliative Care / Q000379:methods*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors